In major depressive disorder, women exhibit higher lifetime prevalence and different antidepressant response rates than men, which illustrates the importance of examining individual differences in the pathophysiology of depression and therapeutic response. In recent years, the consideration of sex in related preclinical research has thus gained interestparticularly in light of novel evidence for rapid-acting antidepressants. Notably, the literature recently revealed a higher sensitivity of females to the antidepressant effects of the N-methyl-D-aspartate receptor antagonist ketamine, in both baseline and preclinical conditions. Combined with its fastacting and relatively sustained properties, this evidence highlights ketamine as a particularly interesting therapeutic alternative for this sensitive population, and supports the value in considering sex as a critical factor for improved individualized therapeutic strategies.
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Introduction
As the global burden of depression continues its rise as the leading cause of disability worldwide [1], the urgent need for more effective treatments is dire. A new wave of excitement, however, has been generated by recent discovery that the N-methyl D-aspartate receptor (NMDAR) antagonist, ketamine, rapidly relieves depressive symptoms and suicidal ideation, particularly amongst those with treatment-resistant depression [2] . Since then, a significant amount of effort has gone into understanding the underlying mechanisms by both preclinical and clinical researchers alike, with the hope of developing novel rapid-acting treatments effective in a broader range of patients [2] .
In the era of personalized medicine, a greater focus on identifying biomarkers or predictors of rapid antidepressant response to ketamine has emerged [3] , but despite the well-established female preponderance in depressive disorders [1] and sex differences in antidepressant efficacy [4], sex has yet to be investigated as a potential moderating variable. Much like genetic and environmental factors, sex is a naturally-occurring disease and treatment modifier [4, 5] , such that factors either protecting against disease or enhancing treatment response in one sex may indicate prevention or treatment strategies in the other sex [6] . This review will highlight recent preclinical evidence demonstrating sex differences in the rapid antidepressant-like response to acute low-dose ketamine, and discuss how a variety of factors including stress, hormonal state, context, and the presence of baseline sex differences, significantly contribute to behavioral or molecular readout following ketamine treatment. This new evidence encourages that sex be seen as an important factor influencing the individual's response to antidepressant treatment rather than a phenotypic dichotomy.
Sex differences in effects of ketamine under baseline conditions
Sex differences in the rapid antidepressant-like effects of ketamine were first reported only a few years ago by work from our lab revealing the heightened sensitivity of female rats to these effects compared to males. These conclusions were demonstrated by the lower dose (2.5 mg/kg) required to rapidly reduce immobility in the forced swim test (FST) and latency to feed in the novelty-suppressed feeding test (NSFT) in naturallycycling female rats compared to their male counterparts [7] . This finding, using FST measures as a behavioral readout, has since been replicated by our lab in rats [8 ] , and corroborated in mice [9 ,10 ] .
Although studies conducted in mice to date have focused solely on intact females, our work in rats demonstrated that this heightened female sensitivity required cyclic fluctuations of both gonadal estradiol and progesterone in female rats [7, 11 ] . This finding has significance, as we
